Skip to main content

Table 6 Adverse events.

From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

  Cycle 1
(n = 74)a
Cycle 2
(n = 61)
Cycle 3
(n = 38)
Cycle 4
(n = 32)
Cycle 5
(n = 19)
Cycle 6
(n = 18)
>Cycle 6
(n = 15)
Overall
(N = 74)
Number of AEs 448 245 128 79 38 28 105 1071
No AEs 7 (9.5)b 7 (11.5) 7 (18.4) 11 (34.4) 7 (36.8) 6 (33.3) 1 (6.7) 1 (1.4)
≥ 1AE 67 (90.5) 54 (88.5) 31 (81.6) 21 (65.6) 12 (63.2) 12 (66.7) 14 (93.3) 73 (98.6)
≥ 1Possibly, probably, or definitely talabostat-related AEs 50 (67.6) 37 (60.7) 14 (36.8) 11 (34.4) 10 (52.6) 10 (55.6) 9 (60.0) 59 (79.7)
≥ 1Grade 3 or 4 AEs 15 (20.3) 11 (18.0) 10 (26.3) 6 (18.8) 4 (21.1) 2 (11.1) 3 (20.0) 42 (56.8)
Discontinued talabostat due to ≥ 1 AE 8 (10.8) 1 (1.6) 0 1 (3.1) 1 (5.3) 0 3 (20.0) 14 (18.9)
≥ 1SAE 9 (12.2) 8 (13.1) 3 (7.9) 2 (6.3) 1 (5.3) 1 (5.6) 0 23 (31.1)
Deaths 10 (13.5) 12 (19.7) 6 (15.8) 5 (15.6) 1 (5.3) 1 (5.6) 4 (26.7) 39 (52.7)
  1. AE = adverse event; SAE = serious adverse event
  2. a Safety population, n = 74.
  3. b N (%) of patients.